Francais
info@saveyourskin.ca

ocular melanoma

Ocular Melanoma Patient & Caregiver Symposium

Date: 
April 15 & 16, 2023

Start Time:
Day 1 – Starts: 12pm EST | 9am PST | 10am MST | 1:30pm NST | 1pm AST

The Symposium is brought to you by Ocumel Canada & will consist of 4 key presenters. This symposium will go over 7 virtual sessions over 2 days and will provide up-todate information on primary and metastatic disease, treatment options, testing, and the psychosocial experience of patients. Patients living with primary and metastatic ocular melanoma will also share their experiences.

Can’t attend that weekend? Register anyway and the recordings will be sent to you as soon as they are available.

Our Key Presenters:

  • Dr. Marcus Butler, Medical Oncologist, Princess Margaret Cancer Centre
  • Dr. Hatem Krema, Director, Ocular Oncology, Princess Margaret Cancer Centre/UHN
  • Dr. Ezekiel Weis, Provincial Medical Lead, Alberta Ocular Brachytherapy Program
  • Monica Tan, Social Worker, Telus Health/ Private Practice

PROGRAM & ADDITIONAL INFORMATION

Program

Start: 12pm EST | 9am PST | 10am MST | 1:30pm NST | 1pm AST

  • Welcome – Nigel Deacon and Kathy Barnard (15 min)
  • Session 1 – Patient Story – Sherry Agriesti (20 min)
  • Session 2 – Presentation: Primary disease – Dr. Weis (45 min)
  • Break (5 min)
  • Session 3 – Patient Story – Mark Jennings (20 min)
    Dr. Krema – Presentation on the value of testing for patients and physicians in making treatment decisions (45 min) followed by a 15 min Q&A
    Castle (Dr. Alsina) and Impact Genetics (Jamie Jessens) –  Presentation on testing (value and availability) and discussion around testing tools – (30 min)

End: 3pm EST | 12pm PST | 1pm MST | 4:30pm NST | 4pm AST

DAY 2

Start: 12pm EST | 9am PST | 10am MST | 1:30pm NST | 1pm AST

  • Welcome – Nigel Deacon and Kathy Barnard (5 min)
  • Session 1 – Patient Story – Candyce Charles (20 min)
  • Session 2 – Presentation on metastatic disease – Dr. Butler (45 min)
  • Break (5 min)
  • Session 3 – Presentation: Psychosocial Experience of the Patient (30 min) followed by a question period (20 mins)
  • Session 4 – Discussion: What Patients and Caregivers Need from Ocumel Canada Moving Forward – What Needs are Not Being Addressed – Nigel Deacon and Kathy Barnard (30 min)
  • Closing – Nigel Deacon and Kathy Barnard (5 min)

End: 3pm EST | 12pm PST | 1pm MST | 4:30pm NST | 4pm AST

Ocumel Canada, an initiative of Save Your Skin Foundation, was formed to increase awareness, advance treatment options, and build a supportive community for those diagnosed with primary and/or metastatic ocular melanoma (OM). Ocumel Canada is in close collaboration with a global Medical Advisory Board and partner patient representation organizations with the endeavour to build on international best practices to improve patient outcomes for Canadians touched by this disease.

This rare cancer is a challenge in so many ways. The small number of diagnoses in Canada does make it difficult for the mainstream Cancer Agencies to provide adequate services. In some provinces and territories, there are no services at all.

Click here to learn more

Read more

Ocular Melanoma Patient & Caregiver Symposium

Happening virtually over two days, April 15 & 16, 2023, the first Canadian OM Patient & Caregiver Symposium will include presentations by Canada’s leading experts in Ocular Oncology and patients living with Primary and Metastatic Ocular Melanoma.
Stay tuned for more details and registration!
Read more

Patient Reported Experience Measures: 2022 Highlights!

In 2022, Save Your Skin Foundation ran three major patient surveys in order to collect patient-reported experience measure data (PREMs): 

  • “The Patient Experience: Systemic Treatment of Adult Cutaneous Melanoma” (April/May)
  •  “The Patient Experience: Treatment of Patients with Ocular Melanoma” (April/May)
  • “Patient Survey: Treatment Plan Decision-Making” (September/October)

Long-form reporting of the data for “The Patient Experience: Treatment of Patients with Ocular Melanoma” and “Patient Survey: Treatment Plan Decision-Making” are available on the Save Your Skin website. “Treatment Plan Decision-Making” was available in both English and French, and was developed in partnership with AIM at Melanoma. The following blog highlights some particularly notable outcomes from these surveys; we hope you find something of interest to you!

 

Highlights from “The Patient Experience: Systemic Treatment of Adult Cutaneous Melanoma”
  • When asked if they would consider it reasonable to receive additional treatments should their melanoma recur at a later stage, 78.26% directly indicated that they would be interested in additional treatments (Q12).
  • When asked specifically about their experiences on Pembrolizumab (Keytruda™), 73.68% reported enduring fatigue as a side effect, followed in frequency of votes by skin rashes (36.84%) and cognitive impairment (26.32%) (Q17). 61.11% found these side effects manageable (Q18).
  • 95.45% of participants indicated that the side effects resulting from this therapy were worth it for the benefits of the treatment (Q19).
  • When asked if they would consider receiving drug therapy from a clinical trial, 77.27% responded that they would, should the need arise. Of the 22.73% that responded “not sure,” several added comments indicating that they would consider it, but would need more information (Q22).

 

Highlights from “The Patient Experience: Treatment of Patients with Ocular Melanoma”
  • 63.63% of our ocular melanoma survey participant pool who have not received genetic testing would like to, suggesting that many patients see this as a worthwhile process (Question 11).
  • Unsurprisingly, eye-related side effects are the most common for patients with ocular melanoma. These include loss of vision (64.51% of responses), eye pain (16.12%), cataracts (9.67%), flashes of light in the eyes (12.9%), dry eyes (3.22%), macular edema (3.22%), and retinopathy (3.22%) (Q16).
  • 82.35% of participants have ongoing follow up appointments/testing every 3-6 months (Q20).
  • 79.31% of responses suggested that if their disease were to progress in the future, they would be interested in receiving additional treatments (Q21).
  • 64.71% of survey participants indicated that if they were offered enrolment in a clinical trial, they would take it (Q24).
  • The most frequently cited side effects by participants receiving KIMMTRAK ® (tebentafusp-tebn) for their ocular melanoma were fatigue and skin rashes (both selected by 50% of participants) (Q28).
  • 100% of patients who received KIMMTRAK ® (tebentafusp-tebn) noted that the side effects of this treatment were worth enduring for the survival benefit (Q30)
  • The most frequently cited barrier to accessing KIMMTRAK ® (tebentafusp-tebn) was having to travel to another city, which was both an inconvenience and a financial hardship (Q31).

 

Highlights from “Patient Survey: Treatment Plan Decision-Making” English language survey
  • When asked what was the most important topic to discuss with their healthcare team at the time of diagnosis out of the following options: “care plan,” “prognosis,” “treatment timeline,” “quality of life,” and “financial considerations,” survey participants selected “prognosis” as their primary concern, followed by “treatment timeline” and then “care plan.” That “quality of life” and “financial considerations” are the lowest priorities suggests that patients care about survival above all else (Q7).
  • Questions nine and ten demonstrated that patients are creating a treatment plan with their healthcare team along their ideal timeline, which is either at the time of diagnosis or between their first and third appointments.
  • The majority of survey participants (76.56%) stated that they understood at least “most” of the cancer-related information provided to them (Q12); however, 32.82% expressed dissatisfaction with the amount and quality of the information they received (Q21).
  • When asked what resource they most frequently turn to for cancer-related information (other than their healthcare team), the internet was cited by 82.54% of participants (Q13)
  • Questions 15 and 16 illustrated that 73.44% of participants feel they had an appropriate amount of input in developing their treatment plan. 
  • When asked to prioritise the following factors when developing a care plan: “dosing schedule/logistics,” “long-term survival,” “risk of adverse events/side effects,” “financial concerns,” and “lifestyle and family implications,” patients ranked “long-term survival” as their highest priority (Q17).
  • When asked to indicate the two most significant challenges they experienced during treatment, the need for emotional support (60.94%) and the impact of physiological symptoms (45.31%) had the highest number of votes (Q27).

 

Highlights from “Patient Survey: Treatment Plan Decision-Making” French language survey
  • When asked what was the most important topic to discuss with their healthcare team at the time of diagnosis out of the following options: “care plan,” “prognosis,” “treatment timeline,” “quality of life,” and “financial considerations,” survey participants selected “care plan” as their primary concern, followed by “prognosis” and then “quality of life” (Q7).
  • Like the English language cohort, the French language survey participants received care plans along their ideal timeline of either at the time of diagnosis or between the first and third appointments (Q9, 10).
  • In the French language survey, a greater percentage of participants indicated having more responsibility for the development of their care plans. Only 27.27% felt “appropriately involved,” while 63.63% indicated that they made the decision more independently (Q15).
  • When asked to prioritise the following factors when developing a care plan: “dosing schedule/logistics,” “long-term survival,” “risk of adverse events/side effects,” “financial concerns,” and “lifestyle and family implications,” the French language patients also ranked “long-term survival” as their highest priority (Q17).
  • When asked whether they felt prepared for treatment, participants had polarised responses; 63.64% reported feeling “entirely prepared for treatment,” while 27.27% were “mostly unprepared for treatment” (Q24).
  • When asked to indicate the two most significant challenges they experienced during treatment, the French language survey participants voted most frequently for physiological symptoms (54.55%), followed by emotional support and a lack of information, which were tied for votes (36.36% each). This suggests that the need for emotional support is more satisfied for the French language survey participants (Q27).

 

The data from patient reported experience measures, sampled above, is instrumental to our operations as a patient group. We consider these reports when we are prioritising our initiatives for the new year, preparing our strategic plans for patient support, education, awareness, health policy, and advocacy, and share them with other stakeholders in the cancer space. We hope this information was valuable to you, and that the new year brings you joy, prosperity, and good health.

Read more

November is Ocular Melanoma Awareness Month

November is Ocular Melanoma Awareness month – and it is the time of year we at Save Your Skin Foundation and Ocumel Canada bring extra public awareness to the importance of dilated eye exams for the detection of ocular melanoma.

Through our work, we will continue the conversation and maintain the #EyeGetDilated campaign beyond November, so that all Canadians can learn about their options for head to toe body health and to include eye checks in their list of doctor exams.

Early detection is incredibly important for many eye diseases, including ocular melanoma. Ocular melanoma is rare, affecting approximately five in a million people. About 200 cases are diagnosed per year in Canada. While it represents only 5% of melanomas, ocular melanoma can be rapid and aggressive, accounting for 9% of melanoma deaths. Also referred to as uveal melanoma, ocular is a more inclusive term; 90% of primary ocular melanoma develops in the choroid.

To read more about the importance of annual dilated eye exams, click on Brianne’s story below:

We are proud to have partnered with the groups BC Doctors of Optometry and Alberta Association of Optometrists!

 

 

 

 

 

 

For more information about Ocumel Canada and the work we do, visit any of the following pages:

OcumelCanada.ca

About Ocular Melanoma

Helpful Links

Resources and Support

If you or someone you know has been diagnosed with primary or metastatic ocular melanoma, connect with our community of support, Canadian bilingual Facebook group:  Ocular Melanoma Connect/Connexion mélanome oculaire 

Read more

Move for Melanoma 2022 – It’s a Wrap

A tremendous THANK YOU to all of our incredibly dedicated participants and generous donors!

74 participants and 20 teams across Canada took part in Move for Melanoma this year! We have been so moved and inspired by this incredible community of patients, families, and friends.

After the success of last year, we once again set ourselves an ambitious goal of raising $75,000. With your help, we ended up surpassing our goal once again this year!


To wrap up this monumental weekend, we’ve created the Recap Video below. We hope you will take a few moments to watch it as we pay tribute to our incredible participants, donors and sponsors across Canada.


We’d also like to highlight the three fundraising teams that raised the most this year.

Team Ocumel Canada

Based in Victoria, BC, Team Captain Nigel Deacon ran a marathon distance to inspire others to donate to this worthy cause. Together with his fellow team members Martin Dawes and Linda Sendall, they raised an incredible $11,760 for ocular melanoma patients.

Check out his team page here.

 


Team Ani’s Keepers

Based in Chilliwack, BC, Ani Davidson and her sisters challenged themselves to complete a combined 10,000 minutes of fitness between them in the month of September – and they crushed that goal, completing 11,820 minutes! Ani is currently undergoing treatment for melanoma.

Check out her team page here.


Team Mela-No-More – In Honour of Laura

Based in Vancouver, BC, Team Mela-No-More raised funds in honour of Laura, whom they lost after a long and courageous fight. Laura was a beautiful and strong woman, wife and mother. The team raised almost $5,370

Check out their team page here.


Finally, we’d like to acknowledge the many businesses that stepped up to support our event this year. Please show them your support!

Read more

Upcoming Webinar: Prognostic Testing and What It Means to Ocular Melanoma Patients

Join us for a free webinar on Wednesday, September 14 at 5pm PST | 8pm EST.

In this webinar, Katherina Alsina, PhD, Castle BioSciences, Dr. Ezekiel Weis, Provincial Medical Lead, Alberta Ocular Brachytherapy Program, and Dr. Marcus Butler, Medical Oncologist, Princess Margaret Cancer Centre, will help patients understand prognostic testing when diagnosed with Ocular Melanoma. They will also discuss options for HCPs for prognostic testing, what it can mean to patients and how it can affect treatment decisions. The presentations will be followed by a live Q&A session.
Click here to register
Read more

Move for Melanoma 2022

Move for Melanoma is an activity challenge that takes place across Canada. The goal of the event is to bring awareness to melanoma, non-melanoma skin cancer and ocular melanoma, while raising funds to support patients affected with these diseases when they need it most.

This year, the event will take place on September 23-25th, 2022. As always, participants will be able to choose a physical challenge of their choice to complete on the weekend of the event. Participants will form teams and, together with their friends and family, try to reach their personal fundraising goals.

To facilitate the whole thing, again this year, we will be using a custom website that allows people to register, donate, solicit donations, track progress and promote the event all in one place. The website also includes many resources for participants to help them get ready, and a Q&A page for more information.

If you’re interested in joining us, please visit Move for Melanoma 2022 and register now.

 

Save Your Skin Foundation is the only organization in Canada that supports skin cancer patients financially when they need it most. All the money raised through your donations goes directly to patients in the form of cab fares, treatment costs, flights, accommodation and other necessary but costly expenses incurred while receiving treatment.

Whether you’re a survivor who wants to bring hope to newly diagnosed patients, the family member or friend of a patient who wants to send a powerful message of solidarity, or a patient who wants to help change the face of cancer for ever, we invite you to take a stand against melanoma and to move with us this September!

Hand in hand, we fight melanoma together!

          

Read more

Big steps forward in OM treatment & support in Canada

Ocumel Canada in the News

As Ocumel Canada continues to support and advocate for patients touched by ocular melanoma (OM), we are happy to see a monumental step forward in the treatment of this disease across Canada. Last week, Health Canada granted a notice of compliance (NOC) for Kimmtrak® (tebentafusp) for the treatment of metastatic ocular melanoma, closely following approvals in the United States, Australia, and the European Union.

Many patients with this rare cancer have been needing to travel from their home provinces coast to coast – to Toronto – for treatment, which is not an ideal situation for any patient, as they need to be close to their home and support system for ease and comfort as they fight this disease. Ocumel Canada is happy to report that in partnership with treating Physicians and Partners we are making progress in this situation and getting patients treated closer to home.

Global News spoke to two patients in this interview, click HERE to watch the recording.

Ocumel Canada and Save Your Skin Foundation applaud Health Canada’s approval of Kimmtrak® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma in HLA-A*02:01-positive adult patients. We now hope that every province and territory will take swift steps to list this drug on their public formularies in order to make this therapy available to patients across Canada.

We thank all patients and their caregivers who shared their experience and feedback to this process. To learn more about this immunotherapy treatment and the approval, read our full press release by clicking HERE.

To add to all of this great news – we wish to invite all Canadian OM patients or caregivers to join the VISION Registry, an online research database created by our friends at CureOM, Melanoma Research Foundation.

The database will allow researchers to better understand ocular melanoma (OM) as well as the needs and preferences of patients. For example, researchers can look at the socio-demographics, genetics, accompanying conditions, and treatments of patients from around the world and any potential links to OM that might exist.

The research will also look at patients’ experience from onset of symptoms to confirmed diagnosis and how that can be improved.

For the VISION Registry to be successful we need as many patients as possible to securely share their data. There is power in numbers!  Please register and add your information to the registry. We are eager to learn together to advance knowledge and eventually find a cure for OM.

(At this time, the registry is available in English only, but we are working on a French-Canadian translation, stay tuned!)

Click here to learn more and join the Vision Registry: https://melanoma.org/visionregistry/

Read more

WEBINAR: Latest news on melanoma/skin cancer/ocular melanoma from ASCO 2022

(le français suit)

Don’t miss our webinar with Dr. Marcus Butler, the Medical Oncology Disease Site Lead for Melanoma/Skin Oncology at Princess Margaret Cancer Centre and Assistant Professor of Medicine at the University of Toronto. He is also the Clinical Director for the Immune Monitoring Team at the Princess Margaret where he focuses on the immunologic impact of anti-cancer immunotherapies.

This webinar reviews late breaking news, key takeaways, clinical data and other updates presented at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois, in June 2022.

Dr. Butler shares his key insights into what the landscape of melanoma, non-melanoma skin cancers, and ocular melanoma treatment looks like for the near future in Canada.

Click HERE to view the recording

 

WEBINAIRE : Mise à jour sur le mélanome/cancer de la peau/mélanome oculaire de l’ASCO 2022

Regardez l’enregistrement du webinaire avec le Dr Marcus Butler, responsable du site d’oncologie médicale pour le mélanome et l’oncologie de la peau au Princess Margaret Cancer Centre et professeur adjoint de médecine à l’Université de Toronto. Il est également le directeur clinique de l’équipe de surveillance immunitaire du Princess Margaret, où il se concentre sur l’impact immunologique des immunothérapies anticancéreuses.

Ce webinaire a passé en revue les dernières nouvelles, les points essentiels, les données cliniques et d’autres mises à jour présentées lors de l’assemblée annuelle de l’American Society of Clinical Oncology (ASCO) qui a eu lieu à Chicago, en Illinois, en juin 2022.

Le Dr Butler a partagé ses idées clés sur ce à quoi ressemble le paysage du traitement du mélanome, des cancers de la peau autres que le mélanome et du mélanome oculaire dans un avenir proche au Canada.

Cliquez ici pour le webinaire

Read more

Check out our national and international Melanoma Awareness Month initiatives!

May is Melanoma and Skin Cancer Awareness Month

This May, Save Your Skin Foundation and Ocumel Canada are running local, national and international campaigns to raise awareness on the importance of prevention and early detection of skin cancers. See a full list of our Melanoma Skin Cancer Month and Ocular Melanoma awareness initiatives HERE.

For the third year in a row, Save your Skin Foundation’s proclamation initiative has invited Canadian municipalities to take a stance against skin cancer and educate their communities on sun safety through mayoral proclamations. Over 38 municipalities across 8 provinces have issued signed Proclamations to proclaim the month of May 2022 ‘Melanoma and Skin Cancer Awareness Month’.  Look for your city on the list here

Members of our SYSF team have also had the honour to present to the Mayors and Councils of a dozen municipalities across the country to share their experiences as patients and spread the message of sun safety and early detection of skin cancer.

Skin check awareness

Save Your Skin Foundation is part of the Global Melanoma Coalition, a group of 43 organizations from 28 different countries bringing the patient voice to the melanoma space. The below videos have been created in collaboration with the Global Coalition.

It’s funny what you can miss when you’re not looking for it. Watch the Global Coalition video and learn the importance of checking your skin for melanoma and skin cancer:

Skin self-exam tutorial

This video covers the ABCD&E warning signs of melanoma and skin cancer, and the seven steps for checking the body. Pauses between the seven steps have been included in the film, so you can simply take your phone or tablet into a bathroom, hit play, and follow the instructions in real time:

 

#EyePatchDay

Having regular eye examinations could save your life! Routine eye tests can lead to early detection of ocular melanoma and many other health issues. However, statistics show that we are not visiting the optometrist as frequently as we should.

Make a commitment to booking an eye exam this month!

Visit OcumelCanada.ca to learn more

Read more